Ignite Creation Date:
2024-05-06 @ 6:12 PM
Last Modification Date:
2024-10-26 @ 2:43 PM
Study NCT ID:
NCT05574881
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-02-26
First Post:
2022-10-05
Brief Title:
Dalpiciclib Fulvestrant Trastuzumab and Pertuzumab in HR Positive HER2 Positive Metastatic Breast Cancer
Sponsor:
Organization:
Fudan University